Suppliers and packagers for LINEZOLID

LINEZOLID

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hetero Labs	LINEZOLID	linezolid	FOR SUSPENSION;ORAL	211813	ANDA	Camber Pharmaceuticals, Inc.	31722-865-25	1 BOTTLE, GLASS in 1 CARTON (31722-865-25) / 150 mL in 1 BOTTLE, GLASS	2022-10-31
Hetero Labs	LINEZOLID	linezolid	FOR SUSPENSION;ORAL	211813	ANDA	American Health Packaging	60687-754-05	1 BOTTLE, GLASS in 1 CARTON (60687-754-05) / 150 mL in 1 BOTTLE, GLASS	2023-08-20
Hikma	LINEZOLID	linezolid	FOR SUSPENSION;ORAL	200068	ANDA	Hikma Pharmaceuticals USA Inc.	0054-0319-50	150 mL in 1 BOTTLE (0054-0319-50)	2015-06-03
Caplin	LINEZOLID	linezolid	SOLUTION;INTRAVENOUS	219558	ANDA	Caplin Steriles Limited	65145-181-10	10 POUCH in 1 CASE (65145-181-10) / 1 BAG in 1 POUCH (65145-181-01) / 300 mL in 1 BAG	2025-12-23
Eugia Pharma	LINEZOLID	linezolid	SOLUTION;INTRAVENOUS	206917	ANDA	Eugia US LLC	55150-242-51	10 POUCH in 1 CARTON (55150-242-51) / 1 BAG in 1 POUCH / 300 mL in 1 BAG	2016-08-04
Fresenius Kabi Usa	LINEZOLID	linezolid	SOLUTION;INTRAVENOUS	204764	ANDA	Fresenius Kabi USA, LLC	63323-713-13	10 BAG in 1 CASE (63323-713-13) / 300 mL in 1 BAG (63323-713-03)	2015-06-22

Linezolid Active Pharmaceutical Ingredient (API) Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for linezolid active pharmaceutical ingredient (API), focusing on key manufacturers, their production capacities, regulatory standing, and the competitive landscape. Information is based on publicly available data, patent filings, and regulatory databases as of the second quarter of 2024.

What is Linezolid and Its Market Significance?

Linezolid is a synthetic oxazolidinone antibiotic. It is the first drug in its class and is primarily used to treat serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Its importance is underscored by its inclusion on the World Health Organization's List of Essential Medicines [1]. The global market for linezolid APIs is influenced by the prevalence of resistant bacterial infections and the availability of generic versions [2].

Who are the Primary Manufacturers of Linezolid API?

Several companies globally manufacture linezolid API. The landscape includes established generic API manufacturers and specialized chemical producers. Key players are identified below, with a focus on their known or reported production capabilities and geographic distribution:

• Teva Pharmaceutical Industries Ltd.: A significant global player in generic pharmaceuticals, Teva has manufacturing sites in various regions, including North America and Europe. While specific linezolid API capacity is not always disclosed, their broad API portfolio suggests substantial capabilities [3].

• Dr. Reddy's Laboratories Ltd.: An Indian multinational pharmaceutical company, Dr. Reddy's is a major API supplier with manufacturing facilities in India. They are known for producing a range of antibiotics, including linezolid [4].

• Lupin Ltd.: Another prominent Indian pharmaceutical company, Lupin operates multiple manufacturing sites globally and is a known producer of generic APIs, including linezolid [5].

• Zydus Lifesciences Ltd. (formerly Cadila Healthcare Ltd.): This Indian pharmaceutical company has a strong presence in API manufacturing and is among the suppliers of linezolid. Their facilities are compliant with international regulatory standards [6].

• Sun Pharmaceutical Industries Ltd.: Sun Pharma, the largest Indian pharmaceutical company, has extensive API manufacturing capabilities. They supply various APIs, including those for antibiotics like linezolid, from their Indian-based facilities [7].

• Cipla Ltd.: Cipla is an Indian multinational pharmaceutical company with a broad API manufacturing base. They are recognized as a supplier for several antibiotic APIs, including linezolid [8].

• Anacor Pharmaceuticals (now a subsidiary of Pfizer Inc.): While Anacor was a pioneer with its topical linezolid formulation (topical oxazolidinone), Pfizer, as the acquirer, manages the API supply chain. Pfizer's internal manufacturing and external sourcing network likely includes linezolid API production [9].

• Sandoz (a Novartis division): As a leading generic pharmaceutical company, Sandoz has global manufacturing operations and a diverse API portfolio. They are a potential supplier or user of linezolid API [10].

• BDR Pharmaceuticals International Pvt. Ltd.: A specialized Indian API manufacturer, BDR Pharmaceuticals is known for producing APIs for critical care and antibiotics, including linezolid. They emphasize cGMP compliance [11].

• Aurobindo Pharma Ltd.: This Indian company is a significant player in the generic API market. Their manufacturing footprint and product offerings include a range of antibiotics, with linezolid as one such API [12].

Table 1: Key Linezolid API Manufacturers and Geographic Presence

Manufacturer	Primary Country of Origin	Known Manufacturing Regions
Teva Pharmaceutical Industries Ltd.	Israel	North America, Europe, Israel
Dr. Reddy's Laboratories Ltd.	India	India, North America, Europe
Lupin Ltd.	India	India, Europe, North America
Zydus Lifesciences Ltd.	India	India, United States, Europe
Sun Pharmaceutical Industries Ltd.	India	India, United States, Europe
Cipla Ltd.	India	India, United States, Europe
Pfizer Inc. (via Anacor acquisition)	United States	Global (internal & outsourced)
Sandoz (a Novartis division)	Switzerland	Global
BDR Pharmaceuticals International	India	India
Aurobindo Pharma Ltd.	India	India, United States, Europe

What are the Regulatory Requirements for Linezolid API Production?

The production of linezolid API is subject to stringent regulatory oversight from health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organisation (CDSCO). Manufacturers must adhere to current Good Manufacturing Practices (cGMP) [13]. Key regulatory considerations include:

• Drug Master Files (DMFs): API manufacturers must submit DMFs to regulatory agencies. A DMF provides confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review the API quality without disclosing proprietary information to the drug product manufacturer [14].

• Facility Inspections: Manufacturing sites undergo regular inspections by regulatory authorities to ensure ongoing compliance with cGMP standards. These inspections cover quality control, batch consistency, impurity profiles, and documentation.

• Impurity Profiling: Strict control over impurities is critical. Regulatory guidelines, such as those from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), set limits for known and unknown impurities [15]. Specific attention is paid to potentially genotoxic impurities.

• Stability Testing: Manufacturers must conduct comprehensive stability studies to establish appropriate storage conditions and retest dates for the API, ensuring its quality over its shelf life.

• Site Registration and Audits: Drug product manufacturers routinely audit their API suppliers to verify quality and regulatory compliance before approving them for use in their finished dosage forms.

Table 2: Key Regulatory Considerations for Linezolid API

Aspect	Description	Relevant Guidelines/Agencies
cGMP Compliance	Adherence to strict manufacturing, testing, and quality assurance protocols.	FDA, EMA, ICH Q7
Drug Master Files	Submission of detailed API manufacturing information to regulatory agencies.	FDA, EMA, Health Canada, PMDA (Japan)
Impurity Control	Identification, qualification, and control of process-related and degradation impurities.	ICH Q3A, ICH Q3B, ICH M7
Stability Studies	Assessment of API quality over time under defined storage conditions.	ICH Q1A
Site Inspections	Periodic audits of manufacturing facilities by regulatory authorities.	FDA, EMA, CDSCO
Supply Chain Traceability	Documenting the origin and movement of raw materials and the API through the supply chain.	Global regulatory requirements, supply chain security initiatives

What is the Patent Landscape for Linezolid?

The patent landscape for linezolid primarily revolves around composition of matter patents, process patents, and formulation patents. The original composition of matter patent for linezolid was held by The Upjohn Company (now part of Pfizer). This patent has long expired, allowing for the entry of generic manufacturers.

• Composition of Matter Patent: The primary patent covering the linezolid molecule itself has expired. This opened the door for generic competition. The original patent was filed in the 1980s, with an expiration that allowed for widespread generic production starting in the late 2000s and early 2010s.

• Process Patents: Manufacturers may hold patents for novel or improved synthesis routes for linezolid API. These patents focus on more efficient, cost-effective, or environmentally friendly methods of production. Companies continuously seek to innovate in API synthesis to gain a competitive edge and reduce manufacturing costs. For example, patents might claim specific catalysts, reaction conditions, or purification techniques.

• Formulation Patents: Patents may also cover specific formulations of linezolid, such as oral tablets, intravenous solutions, or topical applications. These can include patents on specific excipients, crystal forms (polymorphs), or drug delivery systems that offer improved bioavailability, stability, or patient convenience. However, these are typically for branded finished products rather than the API itself.

• Polymorph Patents: Linezolid can exist in different crystalline forms (polymorphs), which can affect its physical properties such as solubility and bioavailability. Patents claiming specific, therapeutically advantageous polymorphs can still be relevant, although the most common forms are likely off-patent or widely accessible.

• New Indications/Combinations: Patents may also be filed for new therapeutic uses of linezolid or its use in combination with other drugs, extending market exclusivity for specific therapeutic applications.

Table 3: Linezolid Patent Expirations and Impact

Patent Type	General Status	Impact on API Market
Composition of Matter	Expired Globally	Facilitates generic API production; increased competition among API suppliers; drives down API pricing.
Process Patents	Active for select routes	Can offer competitive advantages for manufacturers using patented, efficient synthesis methods. May restrict competitors.
Formulation Patents	Active for specific formulations	Primarily affects finished drug products. Limited direct impact on API supply unless formulation requires a specific API grade.
Polymorph Patents	Active for specific polymorphs	Can influence sourcing for specific drug products requiring a patented crystalline form.

What is the Competitive Landscape and Pricing for Linezolid API?

The linezolid API market is characterized by a high degree of competition, driven by the availability of multiple generic manufacturers and the expiration of primary patents. This intense competition leads to significant pricing pressure.

• Dominance of Indian Manufacturers: Indian API manufacturers hold a substantial share of the global linezolid API market. Their competitive advantage stems from lower manufacturing costs, skilled labor, and established expertise in generic API production and regulatory compliance [16].

• Price Sensitivity: The market is highly price-sensitive. Drug product manufacturers seek the lowest possible API prices to remain competitive in the generic finished dosage form market. Bulk purchasing agreements and long-term contracts are common.

• API Purity and Quality: While price is a major factor, quality and regulatory compliance remain paramount. Manufacturers must demonstrate consistent purity and adherence to cGMP standards to win contracts.

• Supply Chain Reliability: Companies prioritize suppliers with a proven track record of reliable supply and robust quality management systems. Any disruption in API supply can have significant consequences for finished drug product manufacturers.

• Emerging Markets: Demand for linezolid API is also growing in emerging markets where the prevalence of resistant bacterial infections is increasing, and access to essential medicines is expanding.

Pricing Trends:

Historically, the price of linezolid API has decreased significantly since the advent of generics. While specific current pricing is proprietary and subject to contract negotiations, industry estimates suggest prices for bulk API can range from tens to a few hundred U.S. dollars per kilogram, depending on quantity, purity, and supplier [17]. Prices are generally lower for large-volume purchases from established, high-capacity manufacturers.

What are the Risks and Opportunities in the Linezolid API Supply Chain?

The linezolid API supply chain presents both risks and opportunities for stakeholders.

Risks:

• Regulatory Scrutiny and Compliance: Increased focus on supply chain integrity and cGMP compliance can lead to costly remediation efforts or supply disruptions if manufacturers fail inspections. Changes in regulatory requirements can necessitate process modifications.

• Geopolitical Instability: Reliance on specific geographic regions for API production (e.g., India) exposes the supply chain to geopolitical risks, trade disputes, or national policies that could affect exports.

• Raw Material Price Volatility: Fluctuations in the cost of key starting materials and intermediates used in linezolid synthesis can impact API production costs and profitability.

• Quality Control Failures: Batch failures, impurity issues, or contamination incidents can lead to product recalls, regulatory actions, and severe reputational damage.

• Competition and Price Erosion: Continued entry of new API manufacturers and ongoing price pressure can erode profit margins for existing suppliers.

• Intellectual Property Disputes: While the core patent has expired, disputes over process patents or specific polymorphs can still arise.

Opportunities:

• Emerging Markets Growth: Increasing healthcare access and the rise of antimicrobial resistance in developing nations present growing demand for linezolid API.

• Process Innovation: Development of more efficient, cost-effective, or environmentally sustainable synthesis routes can provide a competitive advantage and improve profitability.

• Vertical Integration: API manufacturers may seek to integrate backward into key starting materials or forward into finished dosage forms to capture more value.

• Quality Differentiation: Suppliers who consistently demonstrate superior quality, regulatory adherence, and supply chain transparency can command premium pricing and secure long-term contracts.

• Strategic Partnerships: Collaborations between API manufacturers and finished drug product companies can ensure stable supply and joint development initiatives.

• New Formulations and Indications: While patents on these may not directly impact API supply, successful development of new linezolid formulations or uses can sustain or increase demand for the API.

Key Takeaways

• The linezolid API market is highly competitive, dominated by generic manufacturers, particularly from India.
• The expiration of the primary composition of matter patent has driven down API prices and increased the number of suppliers.
• Stringent regulatory compliance (cGMP, DMFs, impurity control) is critical for market access and supplier qualification.
• Key risks include regulatory changes, geopolitical instability, and quality control failures, while opportunities lie in emerging market growth and process innovation.
• Reliability of supply and consistent quality are as important as price for drug product manufacturers.

Frequently Asked Questions

1. Which countries are the largest exporters of linezolid API? India is the largest exporter of linezolid API, followed by China, with significant contributions also from European countries.

2. Are there any remaining patent barriers for linezolid API production? While the primary composition of matter patent is expired, specific process patents for novel synthesis routes or patents on particular polymorphs may still exist and can impact the freedom to operate for some manufacturers.

3. What is the typical lead time for ordering bulk linezolid API from a manufacturer? Lead times can vary significantly but typically range from 4 to 12 weeks for bulk orders, depending on the manufacturer's production schedule, order volume, and existing inventory.

4. How does the regulatory status of an API manufacturer (e.g., FDA inspection history) affect its ability to supply to major markets? A positive inspection history from major regulatory bodies like the FDA or EMA is a prerequisite for supplying to these markets. Any warning letters or import alerts can severely restrict an API manufacturer's ability to do business.

5. What are the key impurities that must be controlled during linezolid API synthesis? Key impurities include residual solvents, process-related impurities (e.g., intermediates, side-reaction products), and degradation products. Specific focus is placed on controlling any potentially genotoxic impurities to very low levels, as per ICH M7 guidelines.

Citations

[1] World Health Organization. (2023). World Health Organization Model List of Essential Medicines 23rd List. Retrieved from https://www.who.int/publications/i/item/WHO-MVP-2023.01 [2] Global Antibiotic Resistance Partnership. (n.d.). AMR Country Profiles. Retrieved from https://garp.org/countries (Note: Specific linezolid market data is often proprietary, general AMR trends influence demand.) [3] Teva Pharmaceutical Industries Ltd. (2023). Annual Report 2023. [4] Dr. Reddy's Laboratories Ltd. (2023). Annual Report 2023. [5] Lupin Ltd. (2023). Annual Report 2023. [6] Zydus Lifesciences Ltd. (2023). Annual Report 2023. [7] Sun Pharmaceutical Industries Ltd. (2023). Annual Report 2023. [8] Cipla Ltd. (2023). Annual Report 2023. [9] Pfizer Inc. (2023). Annual Report 2023. (Information on Anacor acquisition and integrated supply chains.) [10] Novartis AG. (2023). Annual Report 2023. (Information on Sandoz.) [11] BDR Pharmaceuticals International Pvt. Ltd. (n.d.). Product Portfolio. Retrieved from https://bdrpharma.com/products/ [12] Aurobindo Pharma Ltd. (2023). Annual Report 2023. [13] U.S. Food & Drug Administration. (2013). Guidance for Industry: ANDA Submissions – Section II.A.2.f. Analytical Procedures, Method Validation, and Stability Testing. [14] U.S. Food & Drug Administration. (2023). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files [15] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. [16] Indian Pharmaceutical Alliance. (n.d.). API Sector. Retrieved from https://indianpharmaceuticalalliance.com/api-sector/ (General context on India's API strength.) [17] Market research reports from various sources, e.g., Grand View Research, Mordor Intelligence, (data as of late 2023/early 2024, specific pricing proprietary).